The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). We found significantly higher BMI (p < 0.05) and diastolic blood pressure (p < 0.05) in the psoriatic patients. The values of waist circumference and BMI were significantly higher (p < 0.05) in the male patients compared to the men in the control group. The analysis revealed significantly higher CRP (p < 0.001), Lp-PLA2 (p < 0.001), leptin (p < 0.01), and resistin (p < 0.01) levels in the psoriatic patients. Significantly higher levels of CRP (p < 0.01), Lp-PLA2 (p < 0.001), leptin (p < 0.01), and resistin (p < 0.05) were found in the patients with MS compared to the controls with MS. The level of adiponectin was significantly lower (p < 0.01) in the patients with MS. Finally, we found significantly higher level of Lp-PLA2 (p < 0.001) in the group of patients without MS compared to the controls without MS. In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients.

Department of Dermatology and Venereology University Hospital Hradec Kralove 50005 Hradec Kralove Czech Republic

Department of Medical Biophysics Faculty of Medicine in Hradec Kralove Charles University Prague 50038 Hradec Kralove Czech Republic

Department of Transfusion Medicine University Hospital Hradec Kralove 50005 Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology Faculty of Medicine in Hradec Kralove Charles University Prague 50038 Hradec Kralove Czech Republic

Institute of Hygiene and Preventive Medicine Faculty of Medicine in Hradec Kralove Charles University Prague 50038 Hradec Kralove Czech Republic

Institute of Pathological Physiology Faculty of Medicine in Hradec Kralove Charles University Prague 50038 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Parisi R., Symmons D. P. M., Griffiths C. E. M., Ashcroft D. M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377–385. doi: 10.1038/jid.2012.339. PubMed DOI

Deng Y., Chang C., Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clinical Reviews in Allergy & Immunology. 2016;50(3):377–389. doi: 10.1007/s12016-016-8535-x. PubMed DOI

Borska L., Andrys C., Krejsek J., et al. Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs. Journal of Immunology Research. 2014;2014:6. doi: 10.1155/2014/834389.834389 PubMed DOI PMC

Machado-Pinto J., Diniz M. d., Bavoso N. C. Psoriasis: new comorbidities. Anais Brasileiros de Dermatologia. 2016;91(1):8–14. doi: 10.1590/abd1806-4841.20164169. PubMed DOI PMC

Grozdev I., Korman N., Tsankov N. Psoriasis as a systemic disease. Clinics in Dermatology. 2014;32(3):343–350. doi: 10.1016/j.clindermatol.2013.11.001. PubMed DOI

Davidovici B. B., Sattar N., Jörg P. C., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology. 2010;130(7):1785–1796. doi: 10.1038/jid.2010.103. PubMed DOI

Praveenkumar U., Ganguly S., Ray L., Nanda S. K., Kuruvila S. Prevalence of metabolic syndrome in psoriasis patients and its relation to disease duration: a hospital based case-control study. Journal of Clinical and Diagnostic Research. 2016;10(2):WC01–WC05. doi: 10.7860/jcdr/2016/17791.7218. PubMed DOI PMC

Alsufyani M. A., Golant A. K., Lebwohl M. Psoriasis and the metabolic syndrome. Dermatologic Therapy. 2010;23(2):137–143. doi: 10.1111/j.1529-8019.2010.01307.x. PubMed DOI

Xu T., Zhang Y.-H. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. British Journal of Dermatology. 2012;167(6):1345–1350. doi: 10.1111/bjd.12002. PubMed DOI

Abuabara K., Azfar R. S., Shin D. B., Neimann A. L., Troxel A. B., Gelfand J. M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. British Journal of Dermatology. 2010;163(3):586–592. doi: 10.1111/j.1365-2133.2010.09941.x. PubMed DOI PMC

Coimbra S., Catarino C., Santos-Silva A. The triad psoriasis-obesity-adipokine profile. Journal of the European Academy of Dermatology and Venereology. 2016;30(11):1876–1885. doi: 10.1111/jdv.13701. PubMed DOI

Galic S., Oakhill J. S., Steinberg G. R. Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology. 2010;316(2):129–139. doi: 10.1016/j.mce.2009.08.018. PubMed DOI

Ronti T., Lupattelli G., Mannarino E. The endocrine function of adipose tissue: an update. Clinical Endocrinology. 2006;64(4):355–365. doi: 10.1111/j.1365-2265.2006.02474.x. PubMed DOI

Wolk K., Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Reviews in Endocrine and Metabolic Disorders. 2016:1–13. doi: 10.1007/s11154-016-9381-0. PubMed DOI

Chiricozzi A., Raimondo A., Lembo S., et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Review of Clinical Immunology. 2016;12(12):1299–1308. doi: 10.1080/1744666X.2016.1201423. PubMed DOI

Moutzouri E., Tsimihodimos V., Tselepis A. D. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Current Pharmaceutical Design. 2013;19(21):3827–3840. doi: 10.2174/13816128113199990307. PubMed DOI

Litvinova L., Atochin D., Vasilenko M., et al. Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome. Diabetology & Metabolic Syndrome. 2014;6(1, article 137) doi: 10.1186/1758-5996-6-137. PubMed DOI PMC

National Cholesterol Education Program (NCEP) Expert Panel on Detection. Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421. PubMed

Malkic Salihbegovic E., Hadzigrahic N., Cickusic A. J. Psoriasis and metabolic syndrome. Medical Archives. 2015;69(2):85–87. doi: 10.5455/medarh.2015.69.85-87. PubMed DOI PMC

Baran A., Flisiak I., Jaroszewicz J., Swiderska M. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. Journal of Dermatological Treatment. 2015;26(2):134–138. doi: 10.3109/09546634.2014.915917. PubMed DOI

Balci A., Balci D. D., Yonden Z., et al. Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology. 2010;220(1):32–37. doi: 10.1159/000254482. PubMed DOI

Naito R., Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study. The Journal of Dermatology. 2016;43(12):1406–1411. doi: 10.1111/1346-8138.13439. PubMed DOI

Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatologic Clinics. 2015;33(1):41–55. doi: 10.1016/j.det.2014.09.004. PubMed DOI

Visser M., Bouter L. M., McQuillan G. M., Wener M. H., Harris T. B. Elevated C-reactive protein levels in overweight and obese adults. The Journal of the American Medical Association. 1999;282(22):2131–2135. doi: 10.1001/jama.282.22.2131. PubMed DOI

Kondelkova K., Borska L., Andrys C., et al. Selected inflammatory and metabolic markers in psoriatic patients treated with goeckerman therapy. Mediators of Inflammation. 2015;2015:8. doi: 10.1155/2015/979526.979526 PubMed DOI PMC

Coimbra S., Oliveira H., Reis F., et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. Journal of the European Academy of Dermatology and Venereology. 2010;24(7):789–796. doi: 10.1111/j.1468-3083.2009.03527.x. PubMed DOI

Beygi S., Lajevardi V., Abedini R. C-reactive protein in psoriasis: a review of the literature. Journal of the European Academy of Dermatology and Venereology. 2014;28(6):700–711. doi: 10.1111/jdv.12257. PubMed DOI

Coban M., Tasli L., Turgut S., Özkan S., Ata M. T., Akn F. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Annals of Dermatology. 2016;28(1):74–79. doi: 10.5021/ad.2016.28.1.74. PubMed DOI PMC

Vadakayil A. R., Dandekeri S., Kambil S. M., Ali N. M. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatology Online Journal. 2015;6(5):322–325. doi: 10.4103/2229-5178.164483. PubMed DOI PMC

Berg A. H., Scherer P. E. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research. 2005;96(9):939–949. doi: 10.1161/01.RES.0000163635.62927.34. PubMed DOI

Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., Walsh K. Obesity, adiponectin and vascular inflammatory disease. Current Opinion in Lipidology. 2003;14(6):561–566. doi: 10.1097/00041433-200312000-00003. PubMed DOI

Van Gaal L. F., Mertens I. L., De Block C. E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880. doi: 10.1038/nature05487. PubMed DOI

Seven E. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides. Danish Medical Journal. 2015;62(11):p. B5163. PubMed

Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318–1323. doi: 10.1161/01.HYP.0000129281.03801.4b. PubMed DOI

Oh Y. J., Lim H. K., Choi J. H., Lee J. W., Kim N. I. Serum leptin and adiponectin levels in Korean patients with psoriasis. Journal of Korean Medical Science. 2014;29(5):729–734. doi: 10.3346/jkms.2014.29.5.729. PubMed DOI PMC

Campanati A., Ganzetti G., Giuliodori K., et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. International Journal of Dermatology. 2015;54(7):839–845. doi: 10.1111/ijd.12706. PubMed DOI

Johnston A., Arnadottir S., Gudjonsson J. E., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. British Journal of Dermatology. 2008;159(2):342–350. doi: 10.1111/j.1365-2133.2008.08655.x. PubMed DOI PMC

Kaur S., Zilmer K., Kairane C., Kals M., Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. British Journal of Dermatology. 2008;159(6):1364–1367. doi: 10.1111/j.1365-2133.2008.08759.x. PubMed DOI

Kaur S., Zilmer K., Leping V., Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology. 2011;25(11):1328–1333. doi: 10.1111/j.1468-3083.2011.03982.x. PubMed DOI

Gerdes S., Osadtschy S., Rostami-Yazdi M., Buhles N., Weichenthal M., Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4—mediators of comorbidities in patients with psoriasis? Experimental Dermatology. 2012;21(1):43–47. doi: 10.1111/j.1600-0625.2011.01402.x. PubMed DOI

Özdemir M., Yüksel M., Gökbel H., Okudan N., Mevlitoğlu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. Journal of Dermatology. 2012;39(5):443–448. doi: 10.1111/j.1346-8138.2011.01497.x. PubMed DOI

Badoer E., Kosari S., Stebbing M. J. Resistin, an adipokine with non-generalized actions on sympathetic nerve activity. Frontiers in Physiology. 2015;6, article 321 doi: 10.3389/fphys.2015.00321. PubMed DOI PMC

Klok M. D., Jakobsdottir S., Drent M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity Reviews. 2007;8(1):21–34. doi: 10.1111/j.1467-789x.2006.00270.x. PubMed DOI

Çerman A. A., Bozkurt S., Sav A., Tulunay A., Elbaşi M. O., Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. British Journal of Dermatology. 2008;159(4):820–826. doi: 10.1111/j.1365-2133.2008.08742.x. PubMed DOI

Zhou L., Li Y., Xia T., Feng S., Chen X., Yang Z. Resistin overexpression impaired glucose tolerance in hepatocytes. European Cytokine Network. 2006;17(3):189–195. PubMed

Filková M., Haluzík M., Gay S., Šenolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clinical Immunology. 2009;133(2):157–170. doi: 10.1016/j.clim.2009.07.013. PubMed DOI

Takahashi H., Tsuji H., Honma M., Ishida-Yamamoto A., Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Archives of Dermatological Research. 2013;305(2):113–116. doi: 10.1007/s00403-012-1310-9. PubMed DOI

Kizilarslanoğlu M. C., Kara Ö., Yeşil Y., et al. Alzheimer disease, inflammation, and novel inflammatory marker: resistin. Turkish Journal of Medical Sciences. 2015;45(5):1040–1046. doi: 10.3906/sag-1403-55. PubMed DOI

Huang H., Shen E., Tang S., et al. Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids in Health and Disease. 2015;14, article 44 doi: 10.1186/s12944-015-0039-9. PubMed DOI PMC

Tselepis A. D. Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. Journal of Biomedical Research. 2016 doi: 10.7555/jbr.31.20160009. PubMed DOI PMC

Kolodgie F. D., Burke A. P., Skorija K. S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(11):2523–2529. doi: 10.1161/01.ATV.0000244681.72738.bc. PubMed DOI

Cucchiara B. L., Messe S. R., Sansing L., et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009;40(7):2332–2336. doi: 10.1161/strokeaha.109.553545. PubMed DOI

Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. The Lancet. 2010;375(9725):1536–1544. doi: 10.1016/s0140-6736(10)60319-4. PubMed DOI PMC

Tsimikas S., Willeit J., Knoflach M., et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. European Heart Journal. 2009;30(1):107–115. doi: 10.1093/eurheartj/ehn502. PubMed DOI

Holzer M., Wolf P., Curcic S., et al. Psoriasis alters HDL composition and cholesterol efflux capacity. Journal of Lipid Research. 2012;53(8):1618–1624. doi: 10.1194/jlr.M027367. PubMed DOI PMC

Holzer M., Wolf P., Inzinger M., et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. Journal of Investigative Dermatology. 2014;134(3):635–642. doi: 10.1038/jid.2013.359. PubMed DOI PMC

O'Neill S., O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews. 2015;16(1):1–12. doi: 10.1111/obr.12229. PubMed DOI

Rajappa M., Rathika S., Munisamy M., Chandrashekar L., Thappa D. M. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology. 2015;29(1):69–76. doi: 10.1111/jdv.12451. PubMed DOI

Zhu K.-J., Zhang C., Li M., Zhu C.-Y., Shi G., Fan Y.-M. Leptin levels in patients with psoriasis: a meta-analysis. Clinical and Experimental Dermatology. 2013;38(5):478–483. doi: 10.1111/ced.12171. PubMed DOI

Li R. C., Krishnamoorthy P., Derohannessian S., et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clinical and Experimental Dermatology. 2014;39(1):19–24. doi: 10.1111/ced.12250. PubMed DOI PMC

Coimbra S., Oliveira H., Reis F., et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. Journal of the European Academy of Dermatology and Venereology. 2010;24(12):1386–1394. doi: 10.1111/j.1468-3083.2010.03647.x. PubMed DOI

Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis